Integrated Investment Consultants LLC Increases Holdings in Pfizer Inc. (NYSE:PFE)

Integrated Investment Consultants LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 18.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 133,305 shares of the biopharmaceutical company's stock after acquiring an additional 20,420 shares during the period. Integrated Investment Consultants LLC's holdings in Pfizer were worth $3,537,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. WCG Wealth Advisors LLC lifted its stake in Pfizer by 15.3% during the 2nd quarter. WCG Wealth Advisors LLC now owns 32,347 shares of the biopharmaceutical company's stock valued at $905,000 after acquiring an additional 4,295 shares in the last quarter. XTX Topco Ltd raised its holdings in shares of Pfizer by 206.9% in the second quarter. XTX Topco Ltd now owns 73,946 shares of the biopharmaceutical company's stock valued at $2,069,000 after purchasing an additional 49,851 shares during the last quarter. ProVise Management Group LLC lifted its position in shares of Pfizer by 1.7% during the second quarter. ProVise Management Group LLC now owns 128,926 shares of the biopharmaceutical company's stock valued at $3,607,000 after purchasing an additional 2,131 shares in the last quarter. Cowa LLC purchased a new position in Pfizer during the second quarter worth about $232,000. Finally, Intech Investment Management LLC grew its position in Pfizer by 30.3% in the 2nd quarter. Intech Investment Management LLC now owns 725,663 shares of the biopharmaceutical company's stock worth $20,304,000 after purchasing an additional 168,724 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the company's stock in a transaction dated Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the transaction, the director now owns 10,000 shares in the company, valued at $282,400. The trade was a 11.11 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.06% of the company's stock.

Pfizer Stock Performance

Shares of PFE stock traded down $0.19 during trading on Friday, reaching $26.30. 35,146,711 shares of the company's stock traded hands, compared to its average volume of 35,869,448. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company has a market capitalization of $149.06 billion, a P/E ratio of 35.55, a PEG ratio of 0.64 and a beta of 0.64. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm's 50-day moving average is $26.09 and its 200 day moving average is $28.00.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business's quarterly revenue was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.17) earnings per share. Equities research analysts expect that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This is a boost from Pfizer's previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.54%. Pfizer's dividend payout ratio is currently 227.03%.

Analyst Ratings Changes

Several research firms have commented on PFE. Bank of America reissued a "neutral" rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. UBS Group dropped their price target on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Guggenheim reduced their price objective on Pfizer from $35.00 to $33.00 and set a "buy" rating for the company in a research note on Wednesday, December 11th. Wolfe Research assumed coverage on Pfizer in a research note on Friday, November 15th. They set an "underperform" rating and a $25.00 target price on the stock. Finally, Citigroup began coverage on shares of Pfizer in a research report on Friday, October 25th. They set a "neutral" rating and a $30.00 price target for the company. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $32.00.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.